Amgen presents several sub-analyses at ASBMR from the ongoing open-label extension study of the pivotal Phase 3 Prolia fracture trial
14 October 2012 | By Amgen
Data from several Prolia® studies...
List view / Grid view
News
Merck researchers present BMD data from a Phase II study of Odanacatib
13 October 2012 | By Merck
Odanacatib significantly increased BMD following prior alendronate treatment...
Amgen appoints Cynthia Patton Senior Vice President and Chief Compliance Officer
12 October 2012 | By Amgen
Amgen has announced the appointment of Cynthia M. Patton...
New data from Phase 3 studies provide additional evidence supporting treatment effect for oral BG-12 in Multiple Sclerosis
12 October 2012 | By Biogen Idec
New data from studies evaluating oral BG-12...
New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months
12 October 2012 | By Novartis
Gilenya® the first once-daily oral therapy...
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
12 October 2012 | By Sanofi
Sanofi and Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the ECTRIMS...
GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges
11 October 2012 | By GlaxoSmithKline
Greater openness, transparency and collaboration...
NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms
11 October 2012 | By Boehringer Ingelheim
Final guidance issued on the use of alteplase...
TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS
11 October 2012 | By Biogen Idec
Results from 11 company-sponsored TYSABRI presentations...
Pfizer announces top-line results from a Phase 3 long-term safety study of ALO-02
11 October 2012 | By Pfizer
“These top-line data provide evidence of the long-term safety of ALO-02..."
On World Sight Day, Merck and Partners mark 25 years of successful collaboration to help eliminate river blindness
11 October 2012 | By Merck
World Health Organization commends the MECTIZAN® Donation Program on its contribution to near-elimination of river blindness from the Western Hemisphere...
Novartis MS portfolio presence at 28th ECTRIMS annual meeting reinforces long-term commitment to patients and community
10 October 2012 | By Novartis
New data to be presented...
Novasep invests EUR 30 million to build world’s largest chromatography plant for the pharmaceutical industry
10 October 2012 | By ANDREW LLOYD & ASSOCIATES
New plant on its Mourenx, France site to produce a large volume commercial API...
Lonza awarded contract to generate clinical grade iPSCs by the NIH CRM
The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem…
Biogen Idec’s commitment to MS demonstrated through significant scientific data being presented at the 28th ECTRIMS
10 October 2012 | By Biogen Idec
Extensive data from MS franchise...
